Association of the CCR5Δ32 mutation with clinical response and >5-year survival following initiation of first triple antiretroviral regimen

Antiviral Therapy

Volumn 10, Issue 7, 2005, Pages 849-853

  Brumme, Zabrina L ^a,b   Henrick, Bethany M ^a   Brumme, Chanson J ^a   Hogg, Robert S ^a,b   Montaner, Julio S G ^a,b   Harrigan, P Richard ^a,b  

^a ST PAUL S HOSPITAL   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CHEMOKINE RECEPTOR CCR5; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ARTICLE; COHORT ANALYSIS; DEATH; DISEASE COURSE; FEMALE; FOLLOW UP; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; LYMPHOCYTE DEPLETION; MAJOR CLINICAL STUDY; MALE; MUTATION; PATIENT COMPLIANCE; PREDICTION; PRIORITY JOURNAL; SURVIVAL; T LYMPHOCYTE; TREATMENT OUTCOME; VIRUS LOAD; ADULT; CLINICAL TRIAL; GENETICS; MORTALITY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; RISK FACTOR; SURVIVAL RATE; TIME;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DISEASE PROGRESSION; FEMALE; GENOTYPE; HIV INFECTIONS; HUMANS; MALE; MUTATION; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RECEPTORS, CCR5; RISK FACTORS; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 27844483393     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Samson M, Labbe O, Mollereau C, Vassart G & Parmentier M. Molecular cloning and functional expression of a new human CC-chemokine receptor gene. Biochemistry 1996; 35:3362-3367.
2. Deng H, Liu R, Ellmeier W, Choe S, Unutmaz D, Burkhart M, Di Marzio P, Marmon S, Sutton RE, Hill CM, Davis CB, Peiper SC, Schall TJ, Littman DR & Landau NR. Identification of a major co-receptor for primary isolates of HIV-1. Nature 1996; 381:661-666.
3. Huang Y, Paxton WA, Wolinsky SM, Neumann AU, Zhang L, He T, Kang S, Ceradini D, Jin Z, Yazdanbakhsh K, Kunstman K, Erickson D, Dragon E, Landau NR, Phair J, Ho DD & Koup RA. The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nature Medicine 1996; 11:1240-1243.
4. Dean M, Carrington M, Winkler C, Huttley GA, Smith MW, Allikmets R, Goedert JJ, Buchbinder SP, Vittinghoff E, Gomperts E, Donfield S, Vlahov D, Kaslow R, Saah A, Rinaldo C, Detels R & O'Brien SJ. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Science 1996; 273:1856-1862.
5. Guerin S, Meyer L, Theodorou I, Boufassa F, Magierowska M, Goujard C, Rouzioux C, Debre P & Delfraissy JF; SEROCO/HEMOCO Study Group. CCR5 Δ32 Deletion and Response to HAART in HIV-1-Infected Patients. AIDS 2000; 14:2788-2790
6. Kasten S, Goldwich A, Schmitt M, Rascu A, Grunke M, Dechant C, Kalden JR & Harrer T. Positive influence of the Delta32CCR5 allele on response to highly active anti-retroviral therapy (HAART) in HIV-1 infected patients. European Journal of Medical Research 2000; 5:323-328.
7. Bogner JR, Lutz B, Klein HG, Pollerer C, Troendle U & Goebel FD. Association of highly active antiretroviral therapy failure with chemokine receptor 5 wild type. HIV Medicine 2004; 5:264-272.
8. Bratt G, Karlsson A, Leandersson AC, Albert J, Wahren B & Sandstrom E. Treatment history and baseline viral load, but not viral tropism or CCR5 genotype, influence prolonged antiviral efficacy of highly active antiretroviral treatment. AIDS 1998; 12:2193-2202.
9. Brumme ZL, Chan KJ, Dong W, Hogg R, O'Shaughnessy MV, Montaner JS & Harrigan PR. CCR5Delta32 and promoter polymorphisms are not correlated with initial virotogical or immunological treatment response. AIDS 2001; 15:2259-2266.
10. Wit FW, van Rij RP, Weverling GJ, Lange JM & Schuitemaker H. CC chemokine receptor 5 delta32 and CC chemokine receptor 2 641 polymorphisms do not influence the virologic and immunologic response to antiretroviral combination therapy in human immunodeficiency virus type 1-infected patients. Journal of Infectious Diseases 2002; 186:1726-1732.
11. Hogg RS, Yip B, Chan KJ, Wood E, Craib KJ, O'Shaughnessy MV & Montaner JS. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy. JAMA 2001; 286:2568-2577.
12. Brumme ZL, Dong WW, Yip B, Wynhoven B, Hoffman NG, Swanstrom R, Jensen MA, Mullins JI, Hogg RS, Montaner JS & Harrigan PR. Clinical and immunological impact of HIV envelope V3 sequence variation after starting initial triple antiretroviral therapy. AIDS 2004; 18:F1-F9.
13. Hogg RS, Heath K, Bangsberg D, Yip B, Press N, O'Snaughnessy MV & Montaner JS. Intermittent use of triple-combination therapy is predictive of mortality at baseline and after 1 year of follow-up. AIDS 2002; 16:1051-1058.
14. Valdez H, Purvis S, Lederman M, Filingame M & Zimmerman P. Association of the CCR5Δ32 Mutation With Improved Response to Antiretroviral Therapy. JAMA 1999; 282:734-734.
15. Yamashita TE, Phair JP, Munoz A, Margolick JB, Detels R, O'Brien SJ, Mellors JW, Wolinsky SM & Jacobson LP. Immunologic and virologic response to highly active anti-retroviral therapy in the Multicenter AIDS Cohort Study. AIDS 2001; 15:735-746.
16. Samson M, Libert F, Doranz BJ, Rucker J, Liesnard C, Farber CM, Saragosti S, Lapoumeroulie C, Cognaux J, Forceille C, Muyldermans G, Verhofstede C, Burtonboy G, Georges M, Imai T, Rana S, Yi Y, Smyth RJ, Collman RG, Doms RW, Vassart G & Parmentier M. Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR5 chemokine receptor gene. Nature 1996; 382:722-725.
17. Stewart GJ, Ashton LJ, Biti RA, Ffrench RA, Bennetts BH, Newcombe NR, Benson EM, Carr A, Cooper DA & Kaldor JM. Increased Frequency of CCR-5 Δ32 heterozygotes among long-term non-progressors with HIV-1 infection. AIDS 1997; 11:1833-1838.
18. Gonzalez E, Kulkarni H, Bolivar H, Mangano A, Sanchez R, Catano G, Nibbs RJ, Freedman BI, Quinones MP, Bamshad MJ, Murthy KK, Rovin BH, Bradley W, Clark RA, Anderson SA, O'connell RJ, Agan BK, Ahuja SS, Bologna R, Sen L, Dolan MJ & Ahuja SK. The influence of CCL3L1 gene-containing segmental duplications on HIV-1/AIDS susceptibility. Science 2005; 307:1434-1440.
19. Tang J, Wilson CM, Meleth S, Myracle A, Lobashevsky E, Mulligan MJ, Douglas SD, Korber B, Vermund SH & Kaslow RA; REACH Study Group. Reaching for Excellence in Adolescent Care and Health. Host genetic profiles predict virological and immunological control of HIV-1 infection in adolescents. AIDS 2002; 16:2275-2284.